DermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More

For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using their proprietary Emotion Intelligence tool reveals about half of consumers are on the fence about in-person or telemedicine appointments. Jim Durkin, a Founding Partner of The Martec Group, addresses findings. Amgen submits an sNDA to FDA for Otezla for the treatment of adults with mild-to-moderate plaque psoriasis. FDA has granted priority review of the NDA for Incyte’s ruxolitinib cream for atopic dermatitis. The label for Simponi Aria from Janssen Pharmaceutical Company of Johnson & Johnson now includes language regarding improvement in fatigue for adult patients with active psoriatic arthritis and moderately to severely active RA. Dermavant Sciences plans to submit an NDA in the middle of this year for investigational tapinarof cream, 1%. Klisyri ointment 1% is now available from Almirall for the topical treatment of actinic keratosis of the face and scalp.